Literature DB >> 24649422

Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation.

Jun Kishihara1, Shinichi Niwano1, Hiroe Niwano1, Yuya Aoyama1, Akira Satoh1, Jun Oikawa1, Michiro Kiryu1, Hidehira Fukaya1, Yoshihiko Masaki1, Hideaki Tamaki1, Tohru Izumi1, Junya Ako1.   

Abstract

AIMS: We evaluated the effect of carvedilol, a beta-blocker with anti-oxidative action, against the atrial fibrillation (AF) inducibility, the development of atrial remodeling and the oxidative stress markers in a canine AF model. METHODS AND
RESULTS: AF model was produced by performing 6-week rapid atrial stimulation in 15 dogs. The animals were divided into the following three groups: (I) pacing + carvedilol group (n=5); (II) pacing control group (n=5); and (III) non-pacing group (n=5). AF inducibility was gradually increased along the time course in the pacing control group. In the pacing + carvedilol group, the AF inducibility was suppressed especially in the latter phase of protocol in comparison with the pacing control group. Although carvedilol has beta-blocking effect, pacing control and pacing + carvedilol groups did not exhibit difference in the heart rate (177±13 vs. 155±13 bpm, P=0.08). On 8-hydroxy-2'-deoxyguanosine (8-OHdG), dihydroethidium and dichlorodihydrofluorescein diacetate staining, enhanced oxidative stress was observed in the atrial tissue in the pacing control, but not in the pacing + carvedilol group.
CONCLUSIONS: Carvedilol suppressed AF inducibility and oxidative stress in the canine AF model.

Entities:  

Keywords:  Carvedilol; atrial fibrillation (AF); atrial remodeling; beta-blockade; oxidative stress

Year:  2014        PMID: 24649422      PMCID: PMC3943781          DOI: 10.3978/j.issn.2223-3652.2014.02.03

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  16 in total

1.  Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation.

Authors:  M J Mihm; F Yu; C A Carnes; P J Reiser; P M McCarthy; D R Van Wagoner; J A Bauer
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

2.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

3.  Inhomogeneity in the appearance of electrical remodeling during chronic rapid atrial pacing: evaluation of the dispersion of atrial effective refractoriness.

Authors:  M Moriguchi; S Niwano; N Yoshizawa; Y Kitano; J Kojima; K Inuo; J Saitou; T Izumi
Journal:  Jpn Circ J       Date:  2001-04

4.  Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.

Authors:  Andreas Goette; Norbert Schön; Paulus Kirchhof; Günter Breithardt; Thomas Fetsch; Karl Georg Häusler; Helmut U Klein; Gerhard Steinbeck; Karl Wegscheider; Thomas Meinertz
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-12-07

5.  A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation.

Authors:  Young M Kim; Tomasz J Guzik; Yin Hua Zhang; Mei Hua Zhang; Hassan Kattach; Chandi Ratnatunga; Ravi Pillai; Keith M Channon; Barbara Casadei
Journal:  Circ Res       Date:  2005-08-25       Impact factor: 17.367

6.  Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial.

Authors:  John McMurray; Lars Køber; Michele Robertson; Henry Dargie; Wilson Colucci; Jose Lopez-Sendon; Willem Remme; D Norman Sharpe; Ian Ford
Journal:  J Am Coll Cardiol       Date:  2005-02-15       Impact factor: 24.094

7.  Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation.

Authors:  J Christopher Merritt; Mark Niebauer; Khaldoun Tarakji; Donald Hammer; Roger M Mills
Journal:  Am J Cardiol       Date:  2003-09-15       Impact factor: 2.778

8.  Arrhythmogenic difference between the left and right atria during rapid atrial activation in a canine model of atrial fibrillation.

Authors:  Shinichi Niwano; Jisho Kojima; Hidehira Fukaya; Daisuke Sato; Masahiko Moriguchi; Hiroe Niwano; Yoshihiko Masaki; Tohru Izumi
Journal:  Circ J       Date:  2007-10       Impact factor: 2.993

9.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.

Authors:  M C Wijffels; C J Kirchhof; R Dorland; M A Allessie
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

10.  Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model.

Authors:  Michiro Kiryu; Shinichi Niwano; Hiroe Niwano; Jun Kishihara; Yuya Aoyama; Hidehira Fukaya; Yoshihiko Masaki; Tohru Izumi
Journal:  Europace       Date:  2012-03-27       Impact factor: 5.214

View more
  3 in total

1.  Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation.

Authors:  Tazuru Igarashi; Shinichi Niwano; Hiroe Niwano; Tomoharu Yoshizawa; Hironori Nakamura; Hidehira Fukaya; Tamami Fujiishi; Naruya Ishizue; Akira Satoh; Jun Kishihara; Masami Murakami; Junya Ako
Journal:  Heart Vessels       Date:  2018-05-02       Impact factor: 2.037

2.  Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.

Authors:  Ryo Nishinarita; Shinichi Niwano; Hiroe Niwano; Hironori Nakamura; Daiki Saito; Tetsuro Sato; Gen Matsuura; Yuki Arakawa; Shuhei Kobayashi; Yuki Shirakawa; Ai Horiguchi; Naruya Ishizue; Tazuru Igarashi; Tomoharu Yoshizawa; Jun Oikawa; Yoshinobu Hara; Takafumi Katsumura; Jun Kishihara; Akira Satoh; Hidehira Fukaya; Hiroyuki Sakagami; Junya Ako
Journal:  J Am Heart Assoc       Date:  2021-01-05       Impact factor: 5.501

3.  Carvedilol Ameliorates Intrahepatic Angiogenesis, Sinusoidal Remodeling and Portal Pressure in Cirrhotic Rats.

Authors:  Liping Ling; Guangqi Li; Dongxiao Meng; Sining Wang; Chunqing Zhang
Journal:  Med Sci Monit       Date:  2018-11-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.